NICE does not recommend Roche's ocrelizumab for primary progressive MS

The U.K.'s NICE said in an appraisal consultation it does not recommend the use of Ocrevus ocrelizumab from Roche (SIX:ROG; OTCQX:RHHBY) to

Read the full 221 word article

User Sign In